Purchase this article with an account.
Roy Rubinfeld, William Trattler, Gabriela Perez, Charles J. Kaiser, Aaleya Koreishi, Parag Majmudar, Randy J. Epstein, Shamik Bafna, Ranjan Malahotra; To Evaluate Patient Outcomes Following Epithelium-on CXL In Patients Who Received The Treatment In One Or Both Eyes. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6786.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate patient outcomes following Epithelium-On CXL in patients who received the treatment in one or both eyes.
Eyes enrolled in the study underwent Epithelial-On crosslinking, with preservative-free 0.1% isotonic riboflavin for 30 to 90 minutes. Riboflavin loading was stopped once the cornea was determined by slit lamp examination to be saturated. UV light was initiated for 30 minutes after ensuring that the minimum corneal thickness was at least 400 microns. Post-Op measures including corneal hysteresis (CH) and corneal resistance factor (CRF), Pentacam data, and uncorrected and best-spectacle corrected visual acuities were recorded. Eyes evaluated had a minimum follow-up visit of 3 months and a maximum follow up visit of 18.7 months.
There were 181 (127 male and 49 female) eyes pre-operatively with a follow-up range of 3 months minimum to 18.7 months maximum. The mean follow-up time was 10.85 months. 81% of these eyes had a pre-op diagnosis of keratoconus, 15% had post-LASIK Ectasia, and 2% had pellucid marginal degeneration. Average CH values increased post-operatively from 7.3 to 7.8 and average CRF values increased post-operatively from 5.9 to 7.8. Average refractive cylinder decreased from 4.52D to 3.96D. On Pentacam, average 2mm K Astigmatism decreased post-operatively from 5.47 to 4.66 and average Holladay Astigmatism decreased post-operatively from 3.18 to 2.19. 35.8% of eyes experienced no change in the number of lines of BSCVA and 46.4% of eyes gained 1 or more lines. 30.2% of eyes experienced a loss in one or more lines of BSCVA. Average BSCVA pre-Op was 20/145 and post-Op was 20/114.
Epithelium-on corneal collagen cross-linking appears to be a safe and effective treatment for patients with corneal ecstatic disease.
Clinical Trial: :
This PDF is available to Subscribers Only